<DOC>
	<DOCNO>NCT02880514</DOCNO>
	<brief_summary>A prospective , randomize , single-blind , intra-patient control , multicenter study</brief_summary>
	<brief_title>A Clinical Evaluation Propel Mini Sinus Implant Placement Frontal Sinus Ostia Following In-office Dilation</brief_title>
	<detailed_description>This prospective , randomize , single-blind , intra-patient control , multicenter trial 50 subject enrol 15 site across United States . Study subject undergo implant placement one side follow in-office balloon dilation , contralateral side undergoes balloon dilation serf control .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Inclusion Criteria Patient provide write informed consent use form approve review IRB . Patient 18 year age old . Patient willing able comply protocol requirement . Patient CRS define sinonasal inflammation persist 12 week complain least 2 4 follow symptom : nasal blockage/obstruction/congestion , nasal blockage/obstruction/congestion , nasal discharge ( anterior/posterior ) , facial pain/pressure , reduction/loss smell Postendoscopic sinus surgery , patient bilateral obstruction frontal sinus ostia scar and/or polypoid edema . Patient candidate inoffice balloon dilation procedure . In opinion investigator , treatment Propel Mini Sinus Implant adjunct balloon sinus dilation technically feasible clinically indicated frontal sinus ostia . Expanded amount ethmoid sinonasal polyp extend beyond middle meatus grade 3 4 unless reduce prior randomization study . Oralsteroid dependent condition chronic obstructive pulmonary disease ( COPD ) condition . Known history allergy intolerance corticosteroid mometasone furoate . Clinical evidence acute bacterial sinusitis invasive fungal sinusitis . Active viral illness ( e.g. , flu , shingle ) . Clinical evidence disease condition expect compromise survival ability complete followup assessment Day 180 postprocedure . Currently participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>